OCTHF / Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug

Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid Technologies Holdings, discusses with Proactive's Thomas Warner the successful completion of a phas more_horizontal

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) rose 6% following the successful completion of the phase I study for its more_horizontal

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) hailed as a 'major milestone' the successful completion of dosing for all cohorts more_horizontal

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has successfully administered the final dose of its lead drug candidate, OCT46120 more_horizontal

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) hailed a “defining year” for the progress of its leading drug candidates and more_horizontal

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) said it has commenced its phase I clinical trial for the lead drug candidate, OC more_horizontal

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) rose 10% on Monday as the pharmaceutical company formally announced its more_horizontal

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), a pharmaceutical company specialising in prescription cannabinoid medicines, is more_horizontal